| Literature DB >> 23290264 |
Xiao-Yan Liu1, Qian Lu, Xin-Ping Ouyang, Shi-Lin Tang, Guo-Jun Zhao, Yun-Cheng Lv, Ping-Ping He, Hai-Jun Kuang, Yan-Yan Tang, Yuchang Fu, Da-Wei Zhang, Chao-Ke Tang.
Abstract
Apelin has an antiatherogenic function through activating protein kinase C (PKC) to initiate a series of cellular signaling pathways. PKC phosphorylates and stabilizes ATP-binding cassette transporter A1 (ABCA1) through inhibiting its degradation mediated by calpain. Thus, in the present study, we investigated whether apelin-13 affects expression of ABCA1 through PKC signaling. The results showed that apelin-13 dramatically increased cholesterol efflux from THP-1 macrophage-derived foam cells and reduced cellular cholesterol levels. ABCA1 protein but not mRNA levels were dramatically increased by apelin-13, and calpain-induced degradation of ABCA1 and calpain activity were suppressed with treatment of apelin-13. However, the effects of apelin-13 on ABCA1 protein expression, cellular cholesterol efflux and calpain activity were abolished by depletion of PKCα, suggesting the potential important role of PKCα. In addition, apelin-13 was shown to phosphorylate serine residues in ABCA1 through the PKCα pathway. Thus, apelin-13 appears to activate PKCα, phosphorylate ABCA1 and inhibit calpain-mediated proteolysis, thereby promoting cholesterol efflux and reducing foam cell formation. Our study herein described a possible mechanism for understanding the antiatherogenic effects of apelin on attenuating the progression of atherosclerosis.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23290264 DOI: 10.1016/j.atherosclerosis.2012.12.002
Source DB: PubMed Journal: Atherosclerosis ISSN: 0021-9150 Impact factor: 5.162